logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q1 2018
Galmed Pharmaceuticals Ltd.
Topline data from phase 2b study of Aramchol (ARREST)
Nonalcoholic steatohepatitis or NASH
2018
MERRIMACK PHARMACEUTICALS, INC.
Results from phase 2 study of MM-121
Advanced or metastatic non-small cell lung cancer.
Early 2018
Prothena Corporation plc
Topline results from phase 2b trial of NEOD001 (PRONTO)
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
2018
Xencor Inc
Initial data from phase 2 study of XmAb5871
Systemic lupus erythematosus
Q1 2018
Galmed Pharmaceuticals Ltd.
Interim data from phase IIa study of Aramchol (ARRIVE)
HIV-associated lipodystrophy and nonalcoholic fatty liver disease
Early 2018
Alnylam Pharmaceuticals Inc.
Top Line Data from ENDEAVOUR Phase 3 Study with Revusiran
Treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) (familial amyloidotic cardiomyopathy)
1H 2018
Eleven Biotherapeutics, Inc.
Topline data from phase 3 trial of Vicinium
high-grade non-muscle invasive bladder cancer
1H 2018
Ocular Therapeutix Inc.
Topline results from 1st phase 3 trial of OTX-TP
Glaucoma and Ocular Hypertension
Early 2018
Auris Medical Holding AG
Topline results from 2nd phase 3 study of Keyzilen (TACTT3)
acute inner ear tinnitus.
2018
Versartis Inc.
Topline data from phase 3 Japanese trial of Somavaratan
growth hormone deficiency
1H 2018
ALDER BIOPHARMACEUTICALS INC
Topline data from phase 3 study of ALD403 (PROMISE 2)
chronic migraine
Q1 2018
Strongbridge Biopharma plc
Topline data from phase 3 trial of COR-003 (SONICS)
endogenous Cushing’s syndrome
1H 2018
Dermira Inc.
Topline results from phase 3 trial of Olumacostat glasaretil (CLAREOS-1 )
Acne
Early 2018
Pluristem Therapeutics, Inc.
Top line results from phase 2 trial of PLX-PAD
intermittent claudication (IC), a peripheral artery disease (
Q1 2018
AVEO Pharmaceuticals, Inc.
Top line data from phase 3 trial of Tivozanib ( TIVO-3)
advanced renal cell carcinoma
1H 2018
Dermira Inc.
Topline results from phase 3 trial of Olumacostat glasaretil (CLAREOS-2)
Acne
Q1 2018
Axsome Therapeutics, Inc.
Top line data from phase 3 trial of AXS-05 (STRIDE-1)
resistant depression
2018
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-PH)
Liver cirrhosis caused by nonalcoholic steatohepatitis
2018
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-NF)
NASH fibrosis
1H 2018
Biota Pharmaceuticals Inc.
Topline data from phase 2 trial of BTA074
Condyloma caused by human papillomavirus
1H 2018
BeyondSpring Inc.
Interim analysis of non-inferiority of phase 2/3 trial of Plinabulin ( Study 105)
Neutropenia
1H 2018
BeyondSpring Inc.
First data readout from phase 2/3 trial of Plinabulin ( Study 106)
Neutropenia
Q1 2018
Idera Pharmaceuticals, Inc.
Overall Response Rate data from phase 2 portion of Phase 1/2 trial of intratumoral IMO-2125
PD-1 refractory metastatic melanoma
Dec 2017
GALECTIN THERAPEUTICS INC
Topline data from phase II study with GR-MD-02 (NASH-CX)
NASH with cirrhosis
Q4 2017
EYEGATE PHARMACEUTICALS INC
Topline data from confirmatory Phase 3 trial of EGP-437 combination product
Non-infectious anterior uveitis;